Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955744 | 0.94 | LPAR3 (0.44) | LPAR3LPAR2ALDH1A1LMNATSHR | |
| SCHEMBL2382268 | 0.85 | TSHR (0.34) | LPAR3TSHRMAPTMMP1MMP2 | |
| SCHEMBL779433 | 0.80 | TRPM8 (0.45) | LPAR3LPAR2 | |
| SCHEMBL4158403 | 0.79 | PPARD (0.39) | ALDH1A1LAP3TDP1MMP1MMP2 | |
| SCHEMBL776771 | 0.79 | LAP3 (0.34) | LAP3 | |
| SCHEMBL2991058 | 0.78 | SMN1; SMN2 (0.50) | LPAR2ALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL16427895 | 0.77 | LPAR3 (0.50) | LPAR3LPAR2 | |
| SCHEMBL11649168 | 0.77 | LPAR3 (0.50) | LPAR3LPAR2 | |
| SCHEMBL10799957 | 0.77 | LPAR3 (0.50) | LPAR3LPAR2 | |
| SCHEMBL864318 | 0.77 | CYP1A2 (0.47) | LMNATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060280719-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2006-12-14 | — | — | US | disclosed |
| US-7109184-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1485391-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1485391-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040019020-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003080630-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280719-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC43A1 | LPAR3 1651/4885LPAR2 1433/4885ALDH1A1 1561/4885 |
| US-20040019020-A1 | Phosphate transport inhibitors | SLC34A2, SLC43A1, SLC34A1 | LPAR3 2860/4885LPAR2 2181/4885ALDH1A1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.